Eagle Pharmaceuticals announced today that its dantrolene sodium injectable suspension (brand name Ryanodex) has received a patent for the treatment of exertional heat stroke, which will provide coverage through 2023. Patent ‘460 brings the company’s IP surrounding Ryanodex to four issued patents. As the patent coverage surrounding the company’s best-in-class formulation solidifies, Eagle will initiate…
Charles River Laboratories International Galapagos Transaction Update
On March 13 Charles River announced the acquisition of Galapagos NV’s CRO services businesses: Argenta and BioFocus. To finance the acquisition, Charles River used a combination of cash and debt from its existing euro-denominated revolving credit facility. As a result, we estimate 2014 interest expense will increase by $2.8 million, to $9.6 million. CRL trades…
ICON Acquisition of Aptiv Solutions Consistent With Strategy
Monday, March 31, ICON announced its intention to acquire Aptiv Solutions, a provider of global outsourced development services, for roughly $145 million. The company focuses on technology to enable adaptive clinical trials—a nice complement to ICON’s existing software offering through Firecrest and ICONIK. In addition, Aptiv owns an oncology focused full service CRO in Japan.…
Cardinal Health, Inc. Expanding Preferred Products Platform With AccessClosure Acquisition
On Wednesday afternoon, April 2, Cardinal Health announced the acquisition of AccessClosure, a leading U.S. manufacturer of extravascular closure devices. Strategically, this deal provides Cardinal with a platform to expand its preferred products business into another physician preference category—cardiovascular